Erratum to: Bioequivalence and Tolerability Assessment of a Novel Intravenous Ciclosporin Lipid Emulsion Compared to Branded Ciclosporin in Cremophor[®] EL

Karl Henrik Johannes Ehinger · Magnus Joakim Hansson ·
Fredrik Sjövall · Eskil Elmér

Published online: 8 January 2013
© Springer International Publishing Switzerland 2013

Erratum to: Clin Drug Investig
DOI 10.1007/s40261-012-0029-x

A Published-Ahead-of-Print version of this article was made available online at <http://adisonline.com/druginvestigation/toc/publishahead> on 28 November 2012. An error was subsequently identified in that version of the article, and the following correction should be noted:

Section 4, paragraph 6, line 4, which previously read:

“Ciclosporin[®] is currently being investigated as pharmacological therapy in patients undergoing intervention treatment after myocardial infarction (the CIRCUS Phase III study, “Cyclosporine and Prognosis in Acute Myocardial Infarction [MI] Patients”, clinicaltrials.gov identifier NCT01502774).”

Should read:

“CicloMulsion[®] is currently being investigated as pharmacological therapy in patients undergoing intervention treatment after myocardial infarction (the CIRCUS Phase III study, “Cyclosporine and Prognosis in Acute Myocardial Infarction [MI] Patients”, clinicaltrials.gov identifier NCT01502774).”

The online version of the original article can be found under doi:[10.1007/s40261-012-0029-x](https://doi.org/10.1007/s40261-012-0029-x).

K. H. J. Ehinger (✉) · M. J. Hansson · F. Sjövall · E. Elmér
NeuroVive Pharmaceutical AB (publ), Medicon Village,
223 81 Lund, Sweden
e-mail: johannes.ehinger@neurovive.com

K. H. J. Ehinger · M. J. Hansson · F. Sjövall · E. Elmér
Mitochondrial Pathophysiology Unit, Department of Clinical
Sciences, Lund University, Lund, Sweden